Teladoc (TDOC) shares have been on the rise after Citron Research released a report likening them to a “coiled spring” – full of potential, compressed, and ready to surge with the right catalyst. The equity research firm believes that TDOC shares are worth owning for the long term due to the growth potential embedded in its BetterHelp online therapy platform.
Despite being down nearly 45% from its year-to-date high in February, Teladoc stock is still seen as a strong investment opportunity. Citron Research highlights the company’s recent acquisition of UpLift for $30 million as “transformational,” as it could significantly boost Teladoc’s revenue in the future. This acquisition provides Teladoc with the infrastructure to transition BetterHelp into a covered benefit, further solidifying its position in the market.
Citron Research is convinced that Teladoc is currently undervalued, considering its recurring revenue and clear path to profitability. The firm also praises Teladoc for its scale, which is difficult to replicate in the telehealth industry. Additionally, Teladoc’s commitment to integrating artificial intelligence (AI) into its operations is expected to enhance profitability over time.
During a recent conference, Teladoc executives mentioned that a mere 1% increase in conversion could bring the company an additional $40 million in annual revenue. This potential for revenue growth is a strong reason for investors to consider owning TDOC shares.
Overall, Citron remains positive on Teladoc stock as the company continues to remove friction, unlock reimbursement, and integrate mental health into the broader healthcare system. In late April, Teladoc reported strong Q1 results and provided in-line guidance for the current quarter, further bolstering investor confidence.
Wall Street analysts also share Citron’s optimism, with a consensus rating of “Moderate Buy” on TDOC stock. Analysts have set a mean target of approximately $9.22 on shares of Teladoc, indicating a potential upside of around 15% from current levels.
In conclusion, Teladoc’s growth potential, strategic acquisitions, commitment to innovation, and positive outlook from both Citron Research and Wall Street analysts make it a compelling investment opportunity for investors looking to capitalize on the future of telehealth.
